Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis
Journal of the European Academy of Dermatology and Venereology | May 10, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blinded, etanercept- and placebo-controlled study (CIMPACT)
Journal of the American Academy of Dermatology | Apr 19, 2018
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
Journal of the American Academy of Dermatology | Apr 16, 2018
Most read this week